TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03491397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene MicroSpheres
Description: Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
Study: NCT00913302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Training
Description: cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
Study: NCT02876952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Recommendations
Description: Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LOW VOLUME (LW) Supervised exercise
Description: Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
Study: NCT01509664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discount intervention
Description: 50% discount on selected fruits and vegetables at participating supermarket
Study: NCT02748291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months.
Study: NCT02954705

Intervention type: OTHER
Intervention: Non interventional study
Description: This is a non interventional study because all levies are performed during visit planned for the care of patients.

Intervention type: OTHER
Intervention: Non interventional study
Description: This is a non interventional study because all levies are performed during visit planned for the care of patients.
Study: NCT01279837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharyngocise
Description: swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngocise
Description: swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
Study: NCT00935532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0mg, once a week;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
Study: NCT04501393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid intake
Description: Clear oral fluid including water, pulp-free juice and tea or coffee without milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid intake
Description: Clear oral fluid including water, pulp-free juice and tea or coffee without milk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquid intake
Description: Clear oral fluid including water, pulp-free juice and tea or coffee without milk
Study: NCT02012023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low anterior resection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low anterior resection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tube ileostomy
Study: NCT02748291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Department of Health Physical Activity Guidelines
Description: 1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.~4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods.
Study: NCT02500771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABA therapy enhanced with V-Motive software
Description: Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
Study: NCT02012023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: loop ileostomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: accept reversal operation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remove the tube ileostomy
Study: NCT04236687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate
Description: Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Artery embolization of the prostate
Description: A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
Study: NCT03520218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Performance of R-PEM
Description: R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
Study: NCT03960853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure-controlled ventilation-volume guaranteed
Description: patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: volume controlled ventilation
Description: patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
Study: NCT04174209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cylinder
Description: Patients who receive the Jackson Cross Cylinder Method

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dial
Description: Patients who receive the Astigmatic Dial Technique Method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slit
Description: Patients who receive the Stenopeic slit Method.
Study: NCT03735472

Intervention type: DEVICE
Intervention: Thoraflex™ Hybrid
Description: The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch.
Study: NCT00346853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole
Description: 15 mg/kg dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT04217772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography Angiography
Description: A device testing the vascular density in the retina
Study: NCT01539577

Intervention type: DRUG
Intervention: dexamethasone 700 μg intravitreal implant
Description: dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
Study: NCT00947947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Information Program for Safer Sex
Description: Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tailored Information Program for Safer Sex
Description: Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
Study: NCT04262206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
Study: NCT04168281

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: instead of PCI patients will be followed-up with MRI
Study: NCT03387761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg
Study: NCT04201587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Henna application
Description: Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
Study: NCT05716568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast dose reduction, CT-angiography
Description: Contrast dose reduction for CT-angiography in pre-operative aorta

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast dose reduction, CT-angiography
Description: Contrast dose reduction for CT-angiography in pre-operative aorta

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contrast dose reduction, CT-angiography
Description: Contrast dose reduction for CT-angiography in pre-operative aorta
Study: NCT03564353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS
Study: NCT01760798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Study: NCT02033278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of autologous mononuclear bone marrow cells
Description: Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo infusion plus conventional medical treatment (as indicated by clinician)
Study: NCT00467207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Study: NCT01397149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form, frequency and duration exactly as experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to \> 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I.
Study: NCT02786004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Field Digital Mammography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis
Study: NCT02990871

Intervention type: OTHER
Intervention: early neurological rehabilitation
Description: start of neurological rehabilitation between 3rd and 15th day after ABI

Intervention type: OTHER
Intervention: no-early neurological rehabilitation
Description: start of neurological rehabilitation between 20th and 90th day after ABI
Study: NCT03294200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriCinch Coil System implantation
Description: Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
Study: NCT02502747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhu G-CSF
Description: rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal standard of care
Description: Optimal standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial Contrast Echocardiography with sulphur hexafluoride.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial Contrast Echocardiography
Description: Myocardial Contrast Echocardiography with sulphur hexafluoride.
Study: NCT02373631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling, Conventional PT
Description: Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
Study: NCT04516005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
Study: NCT03297502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus cream 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel (pimecrolimus) cream 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02082470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up care
Description: Undergo survivorship care planning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo cancer surveillance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02434159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart scan
Study: NCT01979601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial
Study: NCT02336451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
Study: NCT01979601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGT209
Description: 150 mg lyophilized powder in glass vial
Study: NCT03758547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: in-exufflator technique
Description: application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percussion technique
Description: sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
Study: NCT04700683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noctrix Health NPNS device v1.0 - Active
Description: Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noctrix Health NPNS device v1.0 - Sham
Description: Wearable device programmed to deliver sham stimulation.
Study: NCT01558817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed Assent
Description: Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational Brochure
Description: An informational brochure about CPR will be given without a discussion with a physician.